Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Primo N Lara

Showing results (31-40 of 274) with videos related to

Pageof 28
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung CancerJonathan W Riess, Primo N Lara, David R Gandara
Advances in Urology|March 9, 2012
Progress in personalizing chemotherapy for bladder cancerJames S Chang, Primo N Lara, Chong-Xian Pan
Clinical Genitourinary Cancer|March 18, 2014
Papillary renal cell carcinoma: current progress and future directionsPrzemyslaw W Twardowski, Philip C Mack, Primo N Lara
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 23, 2015
Reply to "diminishing role of platinum-sensitivity status in patients with small cell lung cancer"Primo N Lara, David R Gandara, Mary W Redman
Clinical Lung Cancer|April 28, 2006
Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancerPrimo N Lara, David R Gandara, Ronald B Natale
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2015
Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better MousetrapDavid R Gandara, Primo N Lara, Philip C Mack
JAMA Oncology|June 15, 2018
In Search of an Oncogene Driver for Squamous Lung CancerDavid R Gandara, Jonathan W Riess, Primo N Lara
Lancet (London, England)|November 9, 2024
Adjuvant everolimus after renal cell carcinoma nephrectomy - Authors' replyChristopher W Ryan, Catherine M Tangen, Primo N Lara
Therapeutic Advances in Medical Oncology|July 27, 2011
Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experienceThomas J Semrad, David R Gandara, Primo N Lara
Expert Review of Anticancer Therapy|December 21, 2012
Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the 'common arm' approachPhilip C Mack, David R Gandara, Primo N Lara
Pageof 28

Showing results (31-40 of 274) with videos related to

Sort By:
Pageof 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung CancerJonathan W Riess, Primo N Lara, David R Gandara
Advances in Urology|March 9, 2012
Progress in personalizing chemotherapy for bladder cancerJames S Chang, Primo N Lara, Chong-Xian Pan
Clinical Genitourinary Cancer|March 18, 2014
Papillary renal cell carcinoma: current progress and future directionsPrzemyslaw W Twardowski, Philip C Mack, Primo N Lara
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 23, 2015
Reply to "diminishing role of platinum-sensitivity status in patients with small cell lung cancer"Primo N Lara, David R Gandara, Mary W Redman
Clinical Lung Cancer|April 28, 2006
Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancerPrimo N Lara, David R Gandara, Ronald B Natale
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2015
Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better MousetrapDavid R Gandara, Primo N Lara, Philip C Mack
JAMA Oncology|June 15, 2018
In Search of an Oncogene Driver for Squamous Lung CancerDavid R Gandara, Jonathan W Riess, Primo N Lara
Lancet (London, England)|November 9, 2024
Adjuvant everolimus after renal cell carcinoma nephrectomy - Authors' replyChristopher W Ryan, Catherine M Tangen, Primo N Lara
Therapeutic Advances in Medical Oncology|July 27, 2011
Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experienceThomas J Semrad, David R Gandara, Primo N Lara
Expert Review of Anticancer Therapy|December 21, 2012
Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the 'common arm' approachPhilip C Mack, David R Gandara, Primo N Lara
Pageof 28